You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-HD-22-010: Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)

    Release Date: 03-31-2021Open Date: 06-29-2021Due Date: 07-29-2021Close Date: 07-30-2021

    Purpose/Research Objectives The purpose of this FOA is to stimulate the small business community through the Small Business Innovation Research (SBIR) grant program to adapt discoveries in genomics, epigenomics and biomarker identification to the clinical diagnosis and treatment of couples with infertility, and diseases and disorders that affect fertility. This initiative would foster collaborati ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-NS-21-022: Translational Neural Devices (U44 Clinical Trial Optional)

    Release Date: 04-28-2021Open Date: 06-01-2021 Due Dates: Multiple Close Date: 02-21-2024

    A. Purpose The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical saf ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-HG-21-008: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44 Clinical Trial not Allowed)

    Release Date: 03-30-2021Open Date: 05-26-2021 Due Dates: Multiple Close Date: 02-02-2023

    Purpose This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to innovate and develop the early commercial stages of novel technologies that will enable greater than a one order of magnitude improvement in DNA sequencing, or methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been great ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. U: SF6-Free Routes for Electrical Equipment (S-FREE)

    Release Date: 05-21-2021Open Date: 05-21-2021Due Date: 07-23-2021Close Date: 07-23-2021

    The goal of the Topic is to support development of alternative technologies which substitute SF6 in GIE with alternative gas, alternative gas mixtures, or vacuum-based technologies and address SF6 emissions across the life cycle of the equipment. Within the scope of this program, ARPA-E expects to evaluate the viability and risks associated with alternative gas solutions, identify potential new al ...

    SBIR/STTRPhase I/Phase IIDepartment of EnergyARPA-E
  5. PAR-21-082: NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)

    Release Date: 01-14-2021Open Date: 04-14-2021 Due Dates: Multiple Close Date: 01-15-2024

    Purpose This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. A clinical trial is defined by NIH as: "A research study in which one or more human subjects are prospectivel ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. RFA-TR-21-010: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

    Release Date: 01-13-2021Open Date: 03-13-2021 Due Dates: Multiple Close Date: 01-13-2022

    A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underly multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molecu ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. PAR-21-114: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)

    Release Date: 01-25-2021Open Date: 03-05-2021 Due Dates: Multiple Close Date: 01-06-2024

    Purpose NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases, and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and treat ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. PAR-21-059: linical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 11-19-2020Open Date: 01-22-2021 Due Dates: Multiple Close Date: 09-08-2023

    Background A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints, as well as composite biomarkers or biomarker signatures. Bioma ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PAR-21-057: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 11-19-2020Open Date: 01-22-2021 Due Dates: Multiple Close Date: 09-08-2023

    Background A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints, as well as composite biomarkers or biomarker signatures. Becaus ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. RFA-MH-21-112: Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R43/R44 Clinical Trial Optional)

    Release Date: 11-13-2020Open Date: 01-18-2021 Due Dates: Multiple Close Date: 06-16-2022

    Research Strategy Applications should address the following additional issues: Rationale The rate of death by suicide in the United States has increased each year since 2005, from 11.0/100,000 to 14.8/100,000 of the population in 2018. Distinct subgroups have experienced even greater increases in the rate of suicide deaths during this period. With an estimated 20 suicide attempts per death by s ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government